CARDIoGRAMplusC4D

CARDIoGRAMplusC4D CARDIoGRAMplusC4D is a multinational research consortium that aggregated genome-wide association data to map genetic determinants of coronary artery disease and myocardial infarction. The consortium combined data from multiple cohorts, biobanks, and research groups to enable high-powered meta-analyses linking common and low-frequency variants to cardiovascular phenotypes. Its work integrated genetic epidemiology, statistical genetics, and translational research to inform risk prediction and biological mechanisms.

Background and Consortium Formation

The consortium emerged from collaborations among groups associated with Wellcome Trust, National Institutes of Health, European Commission, Medical Research Council, and major academic centers including Harvard University, University of Oxford, University of Cambridge, Stanford University, and Massachusetts General Hospital. Early contributors included investigators from Karolinska Institutet, University of Copenhagen, McMaster University, University of Toronto, Imperial College London, University College London, University of Pennsylvania, Johns Hopkins University, and University of Washington. Funding and support came from agencies such as European Research Council, Canadian Institutes of Health Research, National Heart, Lung, and Blood Institute, Wellcome Trust Sanger Institute, and philanthropic organizations like Bill & Melinda Gates Foundation. The formation built on prior initiatives including Framingham Heart Study, Atherosclerosis Risk in Communities Study, Rotterdam Study, CARDIoGRAM Consortium, and C4D Consortium to create an expanded meta-analysis platform.

Study Design and Methodology

Design incorporated genome-wide association study (GWAS) meta-analysis strategies developed by teams at Broad Institute, Genentech, deCODE genetics, 23andMe, Illumina, and academic centers like Columbia University, Yale University, and Duke University. Cohorts included case-control datasets from Million Veteran Program, UK Biobank, EPIC-Norfolk, INTERHEART, BioBank Japan, Estonian Biobank, and Netherlands Twin Registry. Quality control and imputation pipelines used reference panels from 1000 Genomes Project, HapMap Project, and Haplotype Reference Consortium, with statistical methods from groups at GlaxoSmithKline, AstraZeneca, Pfizer, and university labs such as University of Michigan and University of Bristol. Analyses applied meta-analysis software from METAL authors, fine-mapping methods by Copenhagen Center for Genomics, and functional annotation leveraging resources from ENCODE Project, Roadmap Epigenomics Consortium, GTEx Consortium, ExAC Consortium, and gnomAD. Population stratification was controlled using methods developed by Pritchard Lab, Price Lab, and teams at University of California, Los Angeles.

Major Findings and Contributions

CARDIoGRAMplusC4D identified dozens of loci associated with coronary artery disease that implicated genes and pathways studied at Harvard Medical School, Yale School of Medicine, University of Cambridge School of Clinical Medicine, and Karolinska University Hospital. Notable discoveries intersected with targets and biology related to LDLR, PCSK9, SORT1, LPA, and loci influencing lipid metabolism and inflammation investigated by researchers at National Heart, Lung, and Blood Institute and American Heart Association. Findings clarified associations overlapping with signals reported in studies from Framingham Heart Study, INTERHEART Study, and CARDIoGRAM Consortium predecessor efforts, and guided functional follow-up in labs at Stanford Medicine, Massachusetts Institute of Technology, Salk Institute, Max Planck Institute, and Francis Crick Institute. The consortium contributed to polygenic risk score development used in projects at Broad Institute, Kings College London, Vanderbilt University Medical Center, and Mount Sinai Health System, and influenced drug target prioritization in programs at Novartis, Regeneron Pharmaceuticals, Merck, and academic translational centers such as UCSF.

Data Resources and Access

Summary statistics and meta-analysis results were disseminated to researchers at institutions like BioVU, Vanderbilt University, FinnGen, UK Biobank, and deCODE genetics under data use agreements consistent with policies from National Institutes of Health, European Medicines Agency, and Wellcome Trust. Data sharing employed platforms and standards promoted by dbGaP, European Genome-Phenome Archive, NIH Data Commons, and infrastructures at ELIXIR and BBMRI-ERIC. Collaborative analyses integrated phenotypes from electronic health record initiatives at Partners HealthCare, Kaiser Permanente, and Mount Sinai, and utilized computing resources at NIH Biowulf, Amazon Web Services, and national supercomputing centers including XSEDE.

Impact on Clinical Genetics and Cardiovascular Research

The consortium’s outputs informed clinical research programs at American College of Cardiology, European Society of Cardiology, National Institute for Health and Care Excellence, and guidelines referenced by World Health Organization. Polygenic risk insights contributed to studies at ClinicalTrials.gov-registered trials and influenced precision medicine initiatives at All of Us Research Program and translational efforts at Sanger Institute. Academia-industry collaborations led to target validation and therapeutic programs in companies such as Amgen, AstraZeneca, Pfizer, and Novo Nordisk. The work also catalyzed follow-up functional studies in model systems at Jackson Laboratory, Wellcome Sanger Institute, EMBL-EBI, University of Zurich, and clinical genomics integration at Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital.

Category:Genetics consortia